SRC
UTHR icon

Sage Rhino Capital’s United Therapeutics UTHR Stock Holding History

Sage Rhino Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
476
+2
+0.4% +$1.13K 0.04% 258
2026
Q1 		$281K Buy
474
+23
+5% +$11.5K 0.05% 200
2025
Q4 		$220K Buy
+451
New +$210K 0.04% 251
2025
Q1 		– Sell
-624
Closed -$220K – 293
2024
Q4 		$220K Hold
624
– – 0.05% 220
2024
Q3 		$224K Buy
+624
New +$211K 0.05% 226

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Sage Rhino Capital's UTHR Position: Q2 2026 in Review

Sage Rhino Capital increased its United Therapeutics (UTHR) stake by 0.42% in Q2 2026, buying an estimated $1.13K and bringing the position to 476 shares worth $258K. The position accounts for 0.04% of the portfolio, ranked #258.

Sage Rhino Capital first reported a position in UTHR in Q3 2024 and has held it in 5 quarters since. The position peaked at $281K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Sage Rhino Capital held 476 shares of United Therapeutics worth $258K as of Q2 2026.
  • Sage Rhino Capital bought 2 United Therapeutics shares in Q2 2026, an estimated $1.13K.
  • United Therapeutics made up 0.04% of Sage Rhino Capital's portfolio in Q2 2026, its #258 holding.
  • Sage Rhino Capital first reported a position in United Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Sage Rhino Capital's United Therapeutics position peaked at $281K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.